|
|
 Previous Article | Table of Contents | Next Article 
Serum levels of soluble intercellular adhesion molecule 1 are increased in
chronic B-lymphocytic leukemia and correlate with clinical stage and
prognostic markers [see comments]
I Christiansen, C Gidlof, AC Wallgren, B Simonsson and TH Totterman
Department of Clinical Immunology and Transfusion Medicine, University
Hospital, Uppsala, Sweden.
The serum levels of soluble intercellular adhesion molecule 1 (ICAM-1) were
significantly elevated (P < .001) in patients with chronic B-
lymphocytic leukemia (B-CLL, n = 113) compared with healthy controls (n =
31). sICAM-1 levels in B-CLL were positively correlated to the tumor mass
as reflected by the modified Rai and the Binet staging systems, lymphocyte
counts, and isolated spleno/hepatomegaly. During disease progression or
regression on cytoreductive therapy, the circulating sICAM-1 levels changed
accordingly. sICAM-1 was also correlated to a kinetic parameter such as the
lymphocyte doubling time. Furthermore, the serum sICAM-1 levels were
inversely correlated to hemoglobin levels in patients with early clinical
stage, and this may turn out to be of prognostic value. sICAM-1 was
compared with other serum markers said to reflect disease activity in
B-CLL, ie, soluble CD23, thymidine kinase, lactate dehydrogenase (LDH), and
beta 2-microglobulin. sICAM-1 was equally well or better correlated to
clinical stage and lymphocyte doubling time. In univariate regression
analysis, all serum markers but LDH correlated with survival, and in
multivariate analysis, sICAM-1 was the only marker approaching significance
for additional prognostic information when included after clinical stage
and lymphocyte doubling time. Based on the present observations, it appears
that prospective studies repeatedly monitoring serum sICAM-1 in B-CLL are
justified.
Volume 84,
Issue 9,
pp. 3010-3016,
11/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Runarsson, A. Liu, Y. Mahshid, S. Feltenmark, A. Pettersson, E. Klein, M. Bjorkholm, and H.-E. Claesson
Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells
Blood,
February 1, 2005;
105(3):
1274 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, S. M. Geyer, and N. E. Kay
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL
Blood,
February 15, 2004;
103(4):
1202 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Terol, M. Tormo, J. A. Martinez-Climent, I. Marugan, I. Benet, A. Ferrandez, A. Teruel, R. Ferrer, and J. Garcia-Conde
Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome
Ann. Onc.,
March 1, 2003;
14(3):
467 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kurosawa, K. Goi, T. Inukai, T. Inaba, K.-S. Chang, T. Shinjyo, K. M. Rakestraw, C. W. Naeve, and A. T. Look
Two Candidate Downstream Target Genes for E2A-HLF
Blood,
January 1, 1999;
93(1):
321 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
